A radioreceptor assay for the analysis of AT1-receptor antagonists correlation with complementary LC data reveals a potential contribution of active metabolites

Journal of Pharmaceutical and Biomedical Analysis

Volumn 17, Issue 1, 1998, Pages 111-124

  Soldner, Andrea ^a,d   Spahn Langguth, Hildegard ^b   Palm, Dieter ^c   Mutschler, Ernst ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

AT1 receptor; EXP 3174; Losartan; Radioreceptor assay; SL 91.0102 90 DL; UP 269 6

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 5 METHYL 7 PROPYL 8 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 2(3H) ONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; LOSARTAN; SL 91 0102 90; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAPERITONEAL DRUG ADMINISTRATION; LIGAND BINDING; LUNG HOMOGENATE; MALE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RADIORECEPTOR ASSAY; RAT; RECEPTOR BLOCKING;

EID: 0032080709     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(97)00240-9     Document Type: Article

References (22)

1. Paul M., Ganten D. J. Cardiovasc. Pharmacol. 19(Suppl. 5):1992;S51-S58.
2. Ganten D. Cardiovasc J. Pharmacol. Suppl. 22(Suppl. 1):1993;S14-S29.
3. Griendling K.K., Murphy T.J., Alexander R.W. Circulation. 87:1993;1816-1828.
4. Timmermans P.B.M.W.M., Carini D.J., Chiu A.T.et al. Hypertension. 18:1991;136-142.
5. Chang R.S.L., Lotti V.J. Mol. Pharmacol. 37:1990;347-351.
6. Whitebread S., Mele M., Kamber B., de Gasparo M. Biochem. Biophys. Res. Commun. 163:1989;284-291.
7. Dudley D.T., Panck R.L., Major T.C.et al. Mol. Pharmacol. 38:1990;370-377.
8. Chiu A.T., Herblin W.F., McCall D.E.et al. Biochem. Biophys. Res. Commun. 165:1989;196-203.
9. Wiest S.A., Rampersaud A., Zimmerman K., Steinberg M.I. J. Cardiovasc. Pharmacol. 17:1991;177-184.
10. Peach M.J., Dostal D.E., Cardiovasc J. J. Cardiovasc. Pharmacol. 16(Suppl. 4):1990;S25-S30.
11. Schinke M., Doods H.N., Ganten D., Wienen W., Entzeroth M. Eur. J. Pharmacol. 204:1991;165-170.
12. Marshall F.H., Clark S.A., Michel A.D., Barnes J.C. Br. J. Pharmacol. 109:1993;760-764.
13. Entzeroth M., Hadamovsky S. Eur. J. Pharmacol. 206:1991;237-241.
14. Montiel M., Quesada J., Jimenez E. J. Endocrinol. 147:1995;153-159.
15. Soldner A., Spahn-Langguth H., Mutschler E. J. Pharm. Biomed. Anal. 16:1988;863-873.
16. Inglessis N., Nussberger J., Hagmann M.et al. J. Cardiovasc. Pharmacol. 25:1995;986-993.
17. McIntyre M., MacFadyen J.R., Meredith P.A.et al. J. Cardiovasc. Pharmacol. 25:1995;994-1000.
18. E.C. Hulme (Ed.), Receptor-Ligands Interactions: a Practical Approach, Oxford University Press, 1992.
19. Cheng Y.C., Prusoff W.H. Biochem. Pharmacol. 2:1973;3099-3108.
20. Lo M.W., Goldberg M.R., McCrea J.B., Lu H., Furtek C.I., Bjornsson T.D. Clin. Pharm. Ther. 58:1995;641-649.
21. Holford N.H.G., Sheiner L.B. Clin. Pharmacokinet. 6:1981;429-453.
22. Stearns R.A., Miller R.R., Doss G.A.et al. Drug Metab. Dispos. 20:1992;281-287.